8-K: Charlottes Web Subsidiary Enters Convertible Note Agreement

Charlottes Web's subsidiary, CW, has entered into a $1.58 million convertible promissory note agreement with DeFloria, Inc., a joint venture involving CW, AJNA BioSciences, and a British American Tobacco subsidiary.

Summary

• Charlottes Web Holdings, Inc. (Company) subsidiary, Charlottes Web, Inc. (CW), has entered into a Convertible Promissory Note (Note) with DeFloria, Inc. (Borrower) for $1,582,500.
• The Note supersedes a prior promissory note and includes accrued interest.
• Interest accrues at 8.0% plus the Bank of England Base Rate, with an initial rate of 11.25% per annum, capped at 14%.
• The Note matures 90 days after demand by majority holders or upon an Event of Default.
• The Note is subject to automatic conversion upon a qualified financing by DeFloria of at least $10,000,000, or optional conversion by CW.
• Conversion occurs at a price based on a valuation cap of $146,000,000.
• Events of Default include payment failures, material breaches, and bankruptcy.
• The Note is unsecured and governed by Delaware law.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the unsecured nature of the note, the potential for dilution upon conversion, and the associated interest rate, despite the strategic alignment with a joint venture.

Positives

• Secures financing for DeFloria, a joint venture involving CW, AJNA BioSciences, and a BAT subsidiary, potentially advancing strategic initiatives.
• The Note includes a valuation cap of $146,000,000, providing a potential upside for CW upon conversion.
• The initial interest rate of 11.25% is within a reasonable range for such instruments, though subject to quarterly resets and a cap.

Negatives

• The Note is unsecured, meaning CW has no collateral to recover in case of default.
• The Note is subject to conversion upon a qualified financing event, which could dilute CW's stake in DeFloria.
• The interest rate is variable and could increase, impacting the cost of capital.
• The maturity date is contingent on demand from majority holders or an Event of Default, creating uncertainty.
• A 20% repayment premium is required upon accelerated repayment, increasing the cost if not converted.

Risks

• Risk of default by DeFloria, Inc., leading to potential loss of principal and accrued interest due to the unsecured nature of the Note.
• Potential dilution of CW's ownership in DeFloria if a qualified financing round occurs at a lower conversion price.
• Uncertainty regarding the maturity date and repayment terms, which are subject to demand by majority holders or events of default.
• The variable interest rate could increase significantly, impacting the overall return and cost.
• The joint venture's success is dependent on the performance of DeFloria and its ability to secure further financing.

Future Outlook

The future outlook for this specific note depends on DeFloria's ability to secure a qualified financing round of at least $10,000,000 or its overall financial performance. If a qualified financing occurs, the Note will convert into preferred stock, potentially providing CW with an equity stake. If not, the maturity and repayment terms are subject to demand and potential default events.

Industry Context

StockSavvy.ai notes that convertible notes are a common financing instrument in early-stage and growth companies, particularly in sectors like biotechnology and consumer packaged goods where Charlottes Web operates. The involvement of a subsidiary of British American Tobacco (BAT) in the DeFloria joint venture is a significant indicator of potential strategic partnerships and validation within the broader cannabis and alternative products industry, which is undergoing significant consolidation and investment.

Comparison to Industry Standards

• Convertible notes are standard for venture debt and bridge financing in the biotechnology and consumer goods sectors. The interest rate of 11.25% (initial) is competitive for such instruments, though the variable component tied to the Bank of England Base Rate adds complexity.
• The valuation cap of $146,000,000 is a key term. In the cannabis and botanical drug development space, valuation caps can vary widely based on the stage of development and market conditions. Without specific comparable financing rounds for DeFloria or similar ventures, it's difficult to definitively benchmark this cap.
• The requirement for a $10,000,000 qualified financing for automatic conversion is a substantial threshold, suggesting DeFloria aims for significant funding rounds. This is typical for companies seeking to scale operations or advance clinical trials.

Related Party Transactions

• DeFloria, the borrower, is a joint venture among CW, AJNA BioSciences, and a subsidiary of British American Tobacco. AJNA BioSciences is partially owned and was co-founded by one of the Company's founders, indicating a related party transaction.

Stakeholder Impact

• Shareholders: Potential dilution of ownership in the subsidiary if the note converts at a low price. However, successful financing and growth of DeFloria could increase the value of CW's investment.
• Creditors: The unsecured nature of the note means creditors of CW would have priority over CW's claim on DeFloria's assets in case of default.
• Suppliers/Partners: The financial health and strategic direction of DeFloria, influenced by this financing, could impact its relationships with suppliers and partners.

Next Steps

• Monitor DeFloria's progress in securing a qualified financing round of at least $10,000,000.
• Await the filing of the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2026, which will include the full text of the Note.
• Observe the performance of the DeFloria joint venture and its strategic initiatives.

Key Dates

Recommendation

The filing details a standard financing arrangement for a subsidiary's joint venture. While the involvement of a major player like BAT is positive, the unsecured nature of the note and the potential for dilution upon conversion introduce risks. The terms are detailed but do not present a significant immediate catalyst for a strong buy or sell recommendation. A 'hold' position allows for further observation of DeFloria's progress and the broader market impact.

Keywords

Convertible Promissory Note, DeFloria, Joint Venture, Financing, Subsidiary, Valuation Cap, Interest Rate, Event of Default